Japanese Approach to colon cancer and the Outcome Dep. of Surgical Oncology Tokyo Medical and Dental University Kenichi Sugihara.

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉財團法人台灣癌症臨床研究發展基金會.

Laparoscopic Surgery for Colon Cancer in Japan. JSCCR Guidelines Laparoscopic surgery Criteria: stage 0 /stage I colon/rectsigmoid cancer Stage II/stage.

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

How to get more nodes in laparoscopic colon surgery John Marks MD Chief Division of Colorectal Surgery Lankenau Hospital and Institute of Medical Research.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.

Evidence Based Decision Making In Gynecologic Cancer Paolo Zola Turin, ITALY Adriana Bermudez Buenos Aires, ARGENTINA.

Stereotactic body radiation therapy for T1N0M0 non-small cell lung cancer. First report for inoperable population of a phase II trial by Japan Clinical.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

NECN Lung NSSG April 2012 Managing Solitary Brain Metastases from NSCLC Dr Paula Mulvenna Consultant Clinical Oncologist Northern Centre for Cancer Care.

Lymphadenectomy in Epithelial Ovarian Cancer

Specialist surgery “Some surgeons perform less than optimal surgery. Some are less competent technically than their colleagues; and some fail to supervise.

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Abstract 8504: E4697: Phase III Cooperative Group Study of Yeast Derived GM-CSF vs Placebo as Adjuvant Treatment of Patients with Completely Resected Stage.

Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.

2014 Cancer Program Performance Outcomes. Introduction Saint Agnes Medical Center has proudly maintained a American College of Surgeons’ Commission on.

Transanal Endoscopic Operation Indication – Technique – Results M. Sailer Department of Surgery Bethesda Hospital – Hamburg, Germany.

Outcomes Following Adjuvant 5-FU based Treatment (AT) for Colon Cancer vs Impact on Recurrence Rate, Time from Recurrence to Death.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.

T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.

CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark Neoadjuvant Therapy For Rectal Cancer: Mature Results.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?

Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.

LLG03999 TN Categorization for Rectal and Colon Cancers Based on National Survival Outcome Data 1 Mayo Clinic Cancer Center – Arizona; Scottsdale, AZ 2.

A three-arm randomized phase III trial of FOLFOX4 vs FOLFOX4 + bevacizumab vs XELOX + bevacizumab in the adjuvant treatment of patients with stage III.

Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.

Laparoscopic vs. Conventional Resections for Colorectal Carcinoma 2LT Pil (Pete) Kang New York University School of Medicine 28 September 2000.

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,

Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: Two decades of experience at Chang Gung Memorial Hospital Yi-Yin Jan, Chun-Nan.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Staging laparoscopy US study: patients with gastric cancer In hospital mortality Staging laparoscopy alone: 5.3% Futile laparotomy: 13.1%

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.

Liver surgery for metachronous hepatic metastases with uterine body and uterine cervix origin – a single center experience Nicolae Bacalbasa (1), Irina.

Short-term outcome of neo-adjuvant chemotherapy

Volume 15, Issue 2, Pages (March 2012)

Cancer Hospital & Institute, Chinese Academy of Medical Sciences

Discussion Gastric Cancer LBA 4002, abstracts 4003, 4004

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

LL Gunderson1, JM Jessup 2, DJ Sargent 3, FL Greene 4, A Stewart 5

Prof. Shaila Anwar Professor Obs & Gynae

Taipei Veterans General Hospital,

Is there a role for adjuvant oxaliplatin in rectal cancer? - YES! -

Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.

Reviewer: Dr Scott Berry Date posted: June 21, 2007

PRESENTATOR: MD VƯƠNG NHẤT PHƯƠNG. HO CHI MINH CITY ONCOLOGY HOSPITAL

Jordan Berlin Co-Director, GI Oncology Program

Adjuvant Radiation is Required for Gastric Cancer

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience Tsuguo Naruke,

2009 TIMELINE PROJECT PLANNING 12 Months Example text Jan Feb March

Alan P. Venook, MD University of California, SF

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

2009 TIMELINE PROJECT PLANNING 12 Months Example text Jan Feb March

Treatment of Stage III Non-small Cell Lung Cancer

Surgical resection of metachronous liver metastases

Presentation transcript:

Japanese Approach to colon cancer and the Outcome Dep. of Surgical Oncology Tokyo Medical and Dental University Kenichi Sugihara

Overall Survival Colon Ca (n=3061) P = year Survival rate Rectal Ca (n=1393) 84.6% 80.6% 1997 〜 2000 in 18 hospitals median follow-up time: 71 months

OS; Stage II Colon Cancer N 5Y-OS 800, 93.5% 914, 88.8% 195, 81.7% 92, 82.1% 128, 91.3% 743, 77.4% 189, 55.5% P< Stage I Stage IIA Stage IIB Stage IIC Stage IIIA Stage IIIB Stage IIIC year Survival rate TNM 7 th ed.

N 5Y-OS 800, 93.5% 914, 88.8% 195, 81.7% 92, 82.1% 128, 91.3% 743, 77.4% 189, 55.5% P< Stage I Stage IIA Stage IIB Stage IIC Stage IIIA Stage IIIB Stage IIIC year Survival rate TNM 7 th ed. OS; Stage III Colon Cancer

Randomized Studies of Adjuvant Chemotherapy in Japan TrialsRegimenDuration (months) StageNo. of Pts Enrolment JCOG02055FU+l-LV vs. UFT+LV ６ Stage III Colon cancer 1101 completed in Nov JCOG0910Capecitabine Vs. S-1 ６ Stage III Colon cancer 1550 started in March 2010 ACTS-CCUFT+LV Vs. S-1 ６ Stage III Colon cancer 1530 completed in June 2009 SACURAUFT vs. surgery alone 12Stage II Colon cancer 2024 completed in July 2010 ACTS-CC 02 UFT+LV vs. SOX ６ anyTN2 Colon cancer 1200 started in April 2010 ACTS-RCUFT vs. S-112Stage II, III Rectal cancer 961 completed in March 2009 JFMC37Capecitabine6 vs 12Stage III Colon cancer 1306 completed in Dec. 2009

UFT/LV vs. 5FU/LV JCOG 0205: Phase III non-inferiority study Stage III Colon Cancer (n=1,101) R UFT/LV (oral) (n=551) 5FU/LV (RPMI) (n=550) Primary endpoint ： DFS Secondary endpoint ： OS, Safety Feb Oct % 75.0 % 73.8 % 90.3 % 94.2% 88.2 % Disease Free Survival Overall Survival

Mortality/Morbidity Surgery of Colon Cancer No. Mortality 118, % rt. colectomy/hemicolectomy No. 39,386 Anastomotic Leakage 1.5% high anterior resection 17,4182.5% National Survey of Digestive Surgery by the Japanese Society of Gastroenterological Surgery 1,191,643 surgeries between 2006 and 2008 high/low anterior resection 55, % APR %

Differences of Colon Cancer Care between Japan and Western  Scope of LN dissection  Histopathological examination of resected specimens  Surveillance after surgery  Strategy for liver metastasis  Medical care system/Medical insurance system JSCCR 

Thank you for your attention